Business Context and Reporting Period
This Form 8-K was filed by OncoCyte Corporation (trading symbol: OCX) on June 11, 2021. The report details the entry into a material definitive agreement to facilitate an at-the-market equity offering.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, or debt levels. The primary financial metric disclosed is the authorization to sell up to $50,000,000 of common stock through the new sales agreement.
Material Changes
The material change reported is the execution of an At-The-Market (ATM) Sales Agreement with BTIG, LLC. Under this agreement:
- The Company may sell up to $50 million of common stock from time to time.
- Sales may be conducted directly on the Nasdaq Stock Market or through a market maker.
- The Company retains control over sale parameters, including timing, volume, and minimum price.
- BTIG, LLC will receive a commission of 3.0% of the gross proceeds from any shares sold.
- The Company has no obligation to sell any shares and may suspend offers at any time.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance or management commentary on future operational outlook. The primary contingency noted is that the sale of shares is subject to the Company's discretion and market conditions. The offering is conducted pursuant to a previously filed Registration Statement on Form S-3 (File No. 333-256650), declared effective on June 8, 2021.
Investor Verification Checklist
- Verify the current share price and potential dilution impact of a $50 million ATM offering.
- Review the Company's cash position in the most recent 10-Q or 10-K to understand the liquidity need driving this offering.
- Monitor future filings for actual sales volumes and proceeds generated under the ATM agreement.
- Confirm the 3.0% commission cost impact on net proceeds.